BioCentury | Dec 31, 2019
Company News
Dec. 31 Company Quick Takes: A first for BeiGene; plus MorphoSys, Junshi-CSPC, Acceleron-Fulcrum and Solasia-EditForce
...digit royalties. Solasia, EditForce partner for gene editing cancer therapies Solasia Pharma K.K. (Tokyo:4597) and EditForce Inc....
...and is eligible for milestones; specific terms were not disclosed. BioCentury Staff Tuoyi, toripalimab (JS001) tislelizumab (BGB-A317) Solasia Pharma K.K. EditForce Inc. BeiGene...
...and is eligible for milestones; specific terms were not disclosed. BioCentury Staff Tuoyi, toripalimab (JS001) tislelizumab (BGB-A317) Solasia Pharma K.K. EditForce Inc. BeiGene...
